This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Struck, L. K. Articles by Dobson, J. K. Search for Related Content PubMed PubMed Citation Articles by Struck, L. K. Articles by Dobson, J. K. Pubmed/NCBI databases Medline Plus Health Information Parkinson's Disease Patient Rights

Stroke, Vol 21, 1395-1399, Copyright © 1990 by American Heart Association

ARTICLES

Stroke and its modification in Parkinson's disease

LK Struck, RL Rodnitzky and JK Dobson
Department of Neurology, University of Iowa College of Medicine, Iowa City.

Previous studies have not agreed on the incidence of ischemic stroke in persons with Parkinson's disease. There are epidemiologic and neurochemical facets of Parkinson's disease that might confer some benefit or protection against ischemic stroke. We used a case-control method to determine the lifetime history of ischemic stroke in 200 patients with Parkinson's disease and 200 controls of a similar age range. Analysis was also carried out for myocardial infarction as a marker of generalized atherosclerotic disease and for stroke risk factors. The cumulative incidence of ischemic stroke was significantly less in the patients with Parkinson's disease than in the controls, as was the cumulative incidence of myocardial infarction. Among risk factors, significantly fewer patients with Parkinson's disease used tobacco than controls. The decreased incidence of ischemic stroke in the patients with Parkinson's disease appears to be related to their less severe generalized atherosclerosis, possibly due to their lower incidence of tobacco use. In view of the known potential for dopamine to exacerbate experimental ischemic tissue damage, the possibility that the dopamine deficiency in the central nervous system of persons with Parkinson's disease confers an additional specific protective benefit against ischemic stroke cannot be excluded and requires further study.

This article has been cited by other articles:

				J. A. Driver, T. Kurth, J. E. Buring, J. M. Gaziano, and G. Logroscino Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study Neurology, April 15, 2008; 70(16_Part_2): 1423 - 1430. [Abstract] [Full Text] [PDF]

				G. Scigliano, M. Musicco, P. Soliveri, I. Piccolo, G. Ronchetti, and F. Girotti Reduced Risk Factors for Vascular Disorders in Parkinson Disease Patients: A Case-Control Study Stroke, May 1, 2006; 37(5): 1184 - 1188. [Abstract] [Full Text] [PDF]

				R. B. Postuma and A. E. Lang Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? Neurology, September 14, 2004; 63(5): 886 - 891. [Abstract] [Full Text] [PDF]

				J. A. Van Gerpen, J. E. Ahlskog, Y. Ben-Shlomo, J. Head, A. Lees, P. T. Donnan, D. T. Steinke, P. G. Davey, and T. M. MacDonald Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study Neurology, July 24, 2002; 57(2): 368 - 370. [Full Text] [PDF]